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Abstract Aspergillus species can cause ocular mor-
bidity and blindness, and thus, appropriate antifungal
therapy is needed. We investigated the in vitro activity
of itraconazole, voriconazole, posaconazole, caspo-
fungin, anidulafungin, and amphotericin B against 14
Aspergillus isolates obtained from patients with ocular
mycoses, using the CLSI reference broth microdilu-
tion methodology. In addition, time-kill assays were
performed, exposing each isolate separately to 1-, 4-,
and 16-fold concentrations above the minimum
inhibitory concentration (MIC) of each antifungal
agent. A sigmoid maximum-effect (Emax) model was
used to fit the time-kill curve data. The drug effect was
further evaluated by measuring an increase/decrease
in the killing rate of the tested isolates. The MICs of
amphotericin B, itraconazole, voriconazole, and
posaconazole were 0.5–1.0, 1.0, 0.5–1.0, and
0.25 lg/ml for A. brasiliensis, A. niger, and A. tubin-
gensis isolates, respectively, and 2.0–4.0, 0.5, 1.0 for
A. flavus, and 0.12–0.25 lg/ml for A. nomius isolates,
respectively. A. calidoustus had the highest MIC range
for the azoles (4.0–16.0 lg/ml) among all isolates
tested. The minimum effective concentrations of
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caspofungin and anidulafungin wereB0.03–0.5 lg/ml
and B0.03 lg/ml for all isolates, respectively.
Posaconazole demonstrated maximal killing rates
(Emax = 0.63 h
-1, r2 = 0.71) against 14 ocular
Aspergillus isolates, followed by amphotericin B
(Emax = 0.39 h
-1, r2 = 0.87), voriconazole (Emax =
0.35 h-1, r2 = 0.098), and itraconazole (Emax =
0.01 h-1, r2 = 0.98). Overall, the antifungal suscep-
tibility of the non-fumigatus Aspergillus isolates tested
was species and antifungal agent dependent. Analysis
of the kinetic growth assays, along with consideration
of the killing rates, revealed that posaconazole was the
most effective antifungal against all of the isolates.
Keywords Non-fumigatus Aspergillus spp. 
Ophthalmic mycoses  Antifungal susceptibility
testing  Time-kill assay
Introduction
Fungal infections of the eye are still an important
cause of ocular morbidity, particularly in developing
countries [1]. Ocular mycoses are difficult to treat
successfully because many fungal genera and species
have been implicated in ocular infections. Notably, it
is difficult to choose an appropriate treatment empir-
ically because drugs are typically selected without
considering the susceptibility data [2, 3]. Moreover,
surgical intervention such as penetrating keratoplasty
may be required for severe mycotic keratitis that
cannot be treated because of the prognosis of empty
lacunae, indicating bone necrosis [4, 5]. Thus, effec-
tive treatment with available antifungal agents is
important to improve the outcome of ocular mycoses,
and therefore, susceptibility testing may help to guide
therapeutic decisions if performed in a timely manner.
In general, polyenes are effective against both
filamentous and yeast forms of fungi. Natamycin is the
only commercially available topical ophthalmic anti-
fungal agent with a broad spectrum of activity against
filamentous organisms, particularly for infections
caused by Fusarium. However, because of poor ocular
penetration, it has primarily been useful in cases with
superficial corneal infection. In addition, topical
amphotericin B is the drug of choice to treat patients
with mycotic keratitis caused by yeasts [6].
Topical 1 % voriconazole has been found to be safe
and effective for the primary management of mycotic
keratitis, with an efficacy matching that of conven-
tional natamycin [7]. In addition, Matsumoto et al. [8]
showed that topical 0.1 % micafungin eyedrops are
comparable to azoles in the treatment of mycotic
keratitis, regardless of the patient’s age, sex, or ulcer
size. Various fungal genera, including Fusarium,
Aspergillus, Candida, Curvularia, Scedosporium
spp., and Schizophyllum commune, frequently infect
ocular structures [9–11]. Although most of the
Aspergillus ocular infections are caused by A. fumiga-
tus, mycotic keratitis caused by non-fumigatus Asper-
gillus species has increased significantly over the past
few years [4]. In a study focusing on the Aspergillus
genus as a causative agent of mycotic keratitis,
A. flavus was found to be the predominant species
(75 %), followed by A. fumigatus and A. terreus, as
determined by molecular identification [12]. In addi-
tion, recent molecular studies revealed that the spec-
trum of Aspergillus species causing mycotic keratitis
is much broader than previously believed and includes
A. pseudotamarii, A. tamarii, A. nomius, A. tubingen-
sis, and A. brasiliensis [13–17].
In the present study, we investigated the in vitro
activity of itraconazole, voriconazole, posaconazole,
caspofungin, anidulafungin, and amphotericin B
against Aspergillus species isolated from the infected
eyes of different patients throughout the world. The
microdilution susceptibility test was performed
according to the guidelines of the Clinical and
Laboratory Standards Institute (CLSI) [18]. In addi-
tion, a microbroth kinetic growth assay was performed
to generate basic pharmacodynamic information on
the relationship between the various concentrations of
the antifungals and the killing rate of each isolate,
according to a maximum-effect (Emax) model, as
described previously [19, 20].
Materials and Methods
Aspergillus Isolates
In total, 14 isolates from different clinical sources were
obtained from the reference culture collection of the
CBS-KNAW Fungal Biodiversity Centre, Utrecht, the
Netherlands. Table 1 shows the origin, identification
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number, and clinical data of each isolate used in the
current study.
Antifungal Drugs
Itraconazole (Janssen, Beerse, Belgium), voriconazole
(Pfizer, New York, NY, USA), posaconazole (Scher-
ing-Plough, Kenilworth, NJ, USA), caspofungin
(Merck, Rahway, NJ, USA), anidulafungin (Pfizer,
NewYork, NY, USA), and amphotericin B (Sigma, St.
Louis, MO, USA) were obtained as standard powders
from their manufacturers. Antifungal stock solutions
were prepared in dimethyl sulfoxide (for itraconazole,
voriconazole, posaconazole, anidulafungin, and
amphotericin B) or distilled water (for caspofungin).
The drug dilutions were prepared in RPMI 1640
medium (Sigma-Aldrich, Steinheim, Germany) buf-
fered to pH 7.0 with 0.165 M MOPS (morpholino-
propanesulfonic acid; Sigma-Aldrich, Steinheim,
Germany). In vitro antifungal susceptibility testing
was performed with the six antifungal compounds
using a broth microdilution format according to the
CLSI guidelines [18], utilizing an XTT dye [19, 21].
The final concentrations of amphotericin B (AMB),
itraconazole (ITC), voriconazole (VRC), posacona-
zole (POS), caspofungin (CAS), and anidulafungin
(AFG) ranged from 0.0313 to 16 lg/ml. The solutions
were dispensed into 96-well microtiter plates and
stored at-70 C until use. The results were read using
a reading mirror and a microtitration plate spectropho-
tometric reader (BIO-TEK, ELX800, USA).
Antifungal Susceptibility Testing
Each isolate was subcultured on potato dextrose agar
(Merck, Darmstadt, Germany) for 7 days at 35 C to
ensure its viability and purity. The fungal colonies were
covered with 1 ml of sterile 0.85 % saline, and a
suspension was prepared by gentle probing of the
colonies. The resulting suspensionswerewithdrawnand
transferred to a sterile tube where the heavy particles
were allowed to settle for 3–5 min, and the upper
homogeneous suspension was transferred to another
sterile tube. The final fungal suspensions were adjusted
to an optical density (OD) of 0.09–0.13 at 530 nm
using a spectrophotometer. These suspensions were
diluted 1:50 in RPMI 1640, and the final inoculum size
was approximately 0.4–5 9 104 CFU/ml. The final
inoculum size was also confirmed with a quantitative
colony count on Sabouraud glucose agar (Merck,
Darmstadt,Germany). Eachwell of themicrotiter plates
was inoculated with 0.1 ml of fungal suspension and
incubated at 35 C, and the minimal inhibitory concen-
trations (MICs)were determined at 48 h.Growth (drug-
free) and sterilized (microorganism-free) control wells
were included for each isolate, and all of the strainswere
evaluated twice for antifungal drug susceptibility.
The MIC endpoints for the azoles and AMB were
defined as the lowest concentration that produced
complete inhibition of growth. Theminimum effective
concentration (MEC) of CAS and AFG was defined as
the lowest concentration at which the fungi display
microscopic morphological changes [18].
Table 1 Origins and
characteristics of
Aspergillus isolates tested
in this study
Species CBS no. Substrate of isolation Country
Aspergillus brasiliensis 122723 Corneal ulcer, human India
A. brasiliensis 122724 Corneal ulcer, human India
A. calidoustus 121609 Post-cataract surgery, endophthalmitis Ankara, Turkey
A. calidoustus 121610 Post-cataract surgery, endophthalmitis Ankara, Turkey
A. flavus 126857 Keratitis Sao Paulo, Brazil
A. flavus 126858 Keratitis Sao Paulo, Brazil
A. flavus 616.94 Orbita tumor, human Aachen, Germany
A. niger 122720 Corneal ulcer, keratitis India
A. niger 122721 Keratitis India
A. niger 122722 Keratitis India
A. nomius 123901 Corneal scraping India
A. tamarii 121598 Keratitis India
A. tubingensis 122719 Corneal ulcer, keratitis India
A. tubingensis 122725 Corneal ulcer, keratitis India
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The quality control strains Paecilomyces variotii
(ATCC 22319), Candida parapsilosis (ATCC 22019),
and Candida krusei (ATCC 6258) were used in all
experiments. The ranges and the geometric means
(GM) of the MIC and MEC were determined for each
species and drug after 48 h of incubation. The MIC50
and MIC90 values were not calculated due to the
limited number of species. If the MIC value of the
replicates was different, the GM values of the
replicates were used for comparison with other
isolates. All experiments were performed in triplicate
on different days.
XTT and Menadione
XTT (Sigma-Aldrich, St. Louis, MO, USA) was
dissolved in saline at a concentration of 1 mg/ml,
and after it was completely dissolved, the solution was
filtered through a filter with a pore size of 0.22 lm.
Menadione (Sigma-Aldrich, St. Louis, MO, USA) was
first dissolved in acetone at a concentration of 10 mM
and then diluted 1:10 in saline. The final solution of
1 mg/ml XTT with 125 lM menadione was prepared
in saline [19, 21].
Colorimetric Microbroth Kinetic Growth Assay
Killing curves were obtained by following a procedure
described previously [20, 22]. Briefly, concentrations
1-, 4-, and 16-fold higher than the determined MIC
were calculated for each antifungal agent. Separate
microplates were used for each time point of incuba-
tion (2, 6, 12, 24, and 48 h). The wells in the first
column included 100 ll of media without drugs
(growth control), and the wells in the fifth column
included 200 ll of media without drugs and conidia
(negative control) in each microplate, which were
processed in the same manner as the inoculated wells.
The next three columns were inoculated with 100 ll of
three different concentrations of ITC, VRC, and AMB
or CAS, AFG, and POS, with the ninth column left
empty. The inoculum suspensions were prepared at a
concentration of 1 9 106 to 5 9 106 conidia/ml and
diluted 1:5 in RPMI 1640. The inoculum suspension
(100 ll) was then inoculated into each well, and all
plates were incubated at 37 C for up to 48 h. Each
plate was taken from the incubator 2 h prior to the end
of the incubation time, and 50 ll of XTT–menadione
solution was added to each well. After 2 h of
incubation with XTT, the formazan absorbance for
each well was read at 450 and 492 nm with a
microplate reader. All experiments were performed
in duplicate on two different days. The results were
evaluated by comparing the absorbance in the growth
with the negative control conditions.
Curve Fitting and Analysis
The experimental data derived from the colorimetric
growth assays were analyzed using GraphPad Prism
5.3 (GraphPad Inc., San Diego, CA, USA) as described
previously [22–24]. Log-transformed optical densities
were plotted against time for each antifungal agent.
The kill ratewas determined at time intervals of 2–48 h
for the azoles and AMB and 2–24 h for the echinocan-
dins via a linear regression analysis. The log-trans-
formed concentrations were then plotted against the
slopes obtained from the linear regression analysis of
the log-transformed optical densities versus time for
each antifungal agent against the 14 tested isolates. The
sigmoidmaximum-effect (Emax:model four-parameter
Hill’s equation) model was used to fit the kill rate data
to determine the pharmacodynamic relationship
between the antifungal concentration and fungal
growth or death. Emax, the 50 % effective concentra-
tion (EC50), was calculated for each assay. The
goodness of fit for the Emax model was checked by R
2
and visual inspection. TheP value of\0.05 (two tailed)
was considered for statistical significance.
Results
The antifungal susceptibility test results for all isolates
are presented in Table 2. Overall, our results indicated
that MIC and MEC endpoints determined by either
visual or spectrophotometric readings were similar.
The MIC values of AMB were from 0.5 to 4.0 lg/ml,
and the lowest MIC values were for A. brasiliensis and
A. niger isolates, whereas the highest MIC value was
for the A. flavus isolate.
ITC MIC values were 0.25 lg/ml for A. tamarii,
4.0 lg/ml for A. calidoustus isolates, and 0.5–1 lg/ml
for the other isolates. The MIC values of VRC were
0.5–1 lg/ml for all isolates except for A. calidoustus,
which had the highest MIC range for azoles
(4.0–16.0 lg/ml) among all of the isolates tested.
The lowest azole MICs were observed with POS;
228 Mycopathologia (2016) 181:225–233
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except for A. calidoustus, all MIC values of POS were
0.12–0.25 lg/ml. The MEC values of echinocandins
were very low; all AFGMECs wereB0.03 lg/ml, and
the CAS MECs were B0.03–0.5 lg/ml. In addition,
the MIC/MEC values of the drugs tested on the quality
control isolates were in acceptable ranges (Table 2).
Figure 1 shows the relationship between the kill rate
and the concentration for all Aspergillus species evalu-
ated. The Emax model was a good fit for the kill rate data.
Posaconazole had the maximal killing rates (Emax =
0.63 h-1, r2 = 0.71) against the 14 ocular Aspergillus
isolates, followed by amphotericin B (Emax = 0.39 h
-1,
r2 = 0.87), voriconazole (Emax = 0.35 h
-1, r2 =
0.098), and itraconazole (Emax = 0.01 h
-1, r2 = 0.98),
indicating that posaconazole was the most effective
antifungal agent against all of the isolates tested.
However, it was not possible to determine the maximal
andhalf-maximumkilling rates forCASandAFGagainst
any of the non-fumigatus Aspergillus species tested.
Discussion
Ocular mycoses are serious infections of the cornea,
orbit, and other ocular structures that may result in
blindness or reduced vision [11]. Successful therapy
for ocular mycoses relies on identification of the
causal agents at the species level and antifungal
susceptibility testing. Importantly, the in vitro suscep-
tibility testing of fungi isolated from ophthalmic
lesions is considered to guide the clinician in the
selection of an appropriate antifungal compound [4].
The pattern of growth and killing rates of all
isolates were further investigated by a microbroth
kinetic growth assay. Both azoles and AMB were the
most potent antifungal agents against all isolates
tested; in contrast, echinocandins did not completely
inhibit the growth of any of the tested isolates in a
concentration-dependent manner.
Recent revisions of the taxonomy of Aspergillus
spp. have had major implications for the understand-
ing of drug susceptibility profiles [23]. New sibling
species of A. fumigatus exhibit in vitro susceptibility
profiles that differ significantly from that of A. fumi-
gatus. Whereas acquired azole resistance is an
emerging problem for A. fumigatus [24, 25], other
Aspergillus spp. may be intrinsically resistant to
specific classes of antifungal agents (Table 2). The
MIC of AMB and azoles for some of the non-
fumigatus Aspergillus spp. was elevated compared
with those for A. fumigatus [23]. The MIC of AMB in
A. flavus clinical isolates was consistently two-fold
Table 2 Geometric mean
MICs obtained by
susceptibility testing of six
antifungal agents
ITC itraconazole,
VRC voriconazole,
POS posaconazole,
CAS caspofungin,
AFG anidulafungin,
AMB amphotericin B,
QC quality control
Species CBS no. MIC/MEC results (lg/ml)
ITC VRC POS CAS AFG AMB
A. brasiliensis 122723 1.0 0.5 0.25 B0.03 B0.03 1.0
A. brasiliensis 122724 1.0 1.0 0.25 0.12 B0.03 0.5
A. calidoustus 121609 4.0 16.0 8.0 0.5 B0.03 2.0
A. calidoustus 121610 4.0 8.0 8.0 0.5 B0.03 2.0
A. flavus 126857 0.5 1.0 0.25 0.25 B0.03 2.0
A. flavus 126858 0.5 1.0 0.12 0.25 B0.03 2.0
A. flavus 616.94 0.5 1.0 0.25 0.12 B0.03 4.0
A. niger 122720 1.0 0.5 0.25 B0.03 B0.03 0.5
A. niger 122721 1.0 0.5 0.25 0.12 B0.03 1.0
A. niger 122722 1.0 0.5 0.25 0.12 B0.03 0.5
A. nomius 123901 0. 5 1.0 0.25 0.12 B0.03 2.0
A. tamarii 121598 0.25 0.5 0.12 0.25 B0.03 1.0
A. tubingensis 122719 1.0 1.0 0.25 0.12 B0.03 1.0
A. tubingensis 122725 1.0 1.0 0.25 0.12 B0.03 1.0
P. variotii (QC) ATCC 22319 0.12 0.06 0.06 B0.015 B0.015 2.0
C. parapsilosis (QC) ATCC 22019 0.5 0.12 0.12 1.0 1.0 1.0
C. krusei (QC) ATCC 6258 0.25 0.25 0.12 1.0 0.06 2.0
Mycopathologia (2016) 181:225–233 229
123
higher than that in A. fumigatus [26]. Using CLSI,
AMB was shown to have MIC values of 1–2 mg/l in
A. nidulans, which was higher than the values
commonly observed with A. fumigatus [27]. In the
section Usti, the azoles were not active against
A. calidoustus, with MICs of C8 mg/l, and the other
classes of antifungal drugs also appeared to be less
active compared with their activity against A. fumiga-
tus. For instance, the MICs of AMB were shown to be
1–2 mg/l, which is relatively high [28]. The resistance
of A. terreus to amphotericin B is well recognized
[29]. Based on azole susceptibility, three different
susceptibility patterns were distinguished in the black
aspergilla, Aspergillus, section Nigri. Azoles showed
low MICs in some isolates and high MICs in other
isolates; a third group of isolates showed an uncom-
mon paradoxical effect. However, these groups did not
coincide with species boundaries, making it difficult to
interpret the difference in MIC as an intrinsic or
acquired property of these molds [30, 31].
In general, voriconazole is the recommended first-
choice drug for the prophylaxis and management of
mycotic endophthalmitis and keratitis against filamen-
tous organisms [32, 33]. However, new-generation
triazoles such as posaconazole have shown good
safety profiles in both laboratory and clinical studies
[34]. In the current study, we also found that
posaconazole had a lower MIC than voriconazole
against all non-fumigatus Aspergillus species except
A. calidoustus isolates, which had the highest MIC
values (C4.0 lg/ml) against all azoles.
The growth and kill curves of POS did not show
apparent inhibition, while ITC and VRC exhibited
persistent inhibition against A. calidoustus isolates at
Fig. 1 Best-fit sigmoid curves obtained from the Emax model of
non-fumigatus Aspergillus species exposed to various antifun-
gals. Posaconazole had the highest Emax (0.63 h
-1, r2 = 0.71),
followed by amphotericin B (0.39 h-1, r2 = 0.87), voricona-
zole (0.35 h-1, r2 = 0.098), and itraconazole (0.01 h-1,
r2 = 0.98). The kill rate was determined at time intervals of
2–48 h via a linear regression analysis. The sigmoid maximum-
effect model was then used to fit the time-kill curve data. The
symbols shown represent slopes obtained from linear regression
analysis of log-transformed optical densities versus time for
each antifungal agent against 14 isolates
230 Mycopathologia (2016) 181:225–233
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concentrations equal to or higher than the MIC. This
newly described isolate is considered to be a relatively
rare human pathogen but appears to represent an
emerging problem, as A. calidoustus isolates have
been found to be triazole resistant in several recent
studies [28, 35–37]. Although our findings reaffirm the
elevated triazole MIC for A. calidoustus isolates, the
POS resistance was more evident when using the time-
kill method with the XTT colorimetric assay in our
in vitro study. ITC and VRC exhibited prominent
inhibition at concentrations equal to or higher than the
MIC, even though the MIC was elevated. In this
scenario, topical usage of ITC and VRC at higher
doses may be promising for treatment of ocular
infections caused by A. calidoustus. However, varia-
tion in the activity of the itraconazole should be
considered depending on the type of Aspergillus
species. In studies reported by an Indo-Hungarian
group, itraconazole showed a higher in vitro MIC in A.
tubingensis isolates obtained from mycotic keratitis
[12, 16].
CAS and AFG had the lowest MEC values against
all of the Aspergillus isolates tested; however, they did
not exhibit concentration-dependent inhibition of
fungal growth in the time-kill assay, possibly because
of the heterogeneous growth characteristics of Asper-
gillus spp. [21] and the paradoxical effects of
echinocandins [38]. In several recent in vitro studies
incorporating ocular isolates, CAS and AFG presented
excellent activity against various Aspergillus species
in the broth microdilution method, in which the MEC
values were low (B0.008–1 lg/ml for CAS and
B0.001–0.015 lg/ml for AFG) [2, 39–42]. Similar to
our study, Lockhart et al. determined the echinocandin
MEC values for caspofungin, micafungin, and anidu-
lafungin against 288 Aspergillus isolates prospectively
collected from transplant patients [43]. The MEC
ranges for A. flavus, A. niger, A. calidoustus, and
A. tubingensis were, respectively: 0.008–0.03 lg/ml
for CAS and 0.008–0.015 lg/ml for AFG,
0.015–0.5 lg/ml for CAS and 0.008–0.03 lg/ml for
AFG, 0.03–4 lg/ml for CAS and 0.008–0.06 lg/ml
for AFG, and 0.015–0.03 lg/ml for CAS and
0.008 lg/ml for AFG [43].
In comparison with the other antifungal agents
tested, we observed that the MIC of AMB tended to be
higher against various Aspergillus species, which is
similar to the findings reported in other studies
including both ocular [2, 11, 44] and non-ocular
isolates [28, 35, 42], with MIC values of B4 lg/ml. In
our study, the time-killing assay of AMB demon-
strated complete concentration-dependent inhibition
of the growth of all isolates.
Of note, as discussed above, the results of the time-
kill studies performed in the current study provided a
more dynamic assessment of the interaction between
the antifungals and the fungi isolated from ocular
lesions than the static MIC determinations did. This
indicates that the time-kill assay may have a greater
clinical utility for guiding therapy in an individual
patient. However, it should be noted that in the clinical
setting, standardized in vitro MIC studies are easier to
perform than monitoring of fungal growth in the time-
kill kinetic system.
Furthermore, for an adequate therapeutic response,
in addition to choosing an antifungal drug with a high
level of activity against the etiological ocular patho-
gen, the drug must be non-irritating and non-toxic to
the eye and penetrate well through the corneal layers
[45]. Depending on the etiologic agent and the
location and extent of the infection in the eye, various
antifungal agents and several routes of administration,
including intravenous, oral, topical, subconjunctival,
intrastromal, intracameral, and intravitreal, should be
considered [33]. Natamycin is the only commercially
available topical antifungal agent approved by the US
Food and Drug Administration (FDA) for ophthalmic
use [33, 46]. Alternatively, topical administration of
econazole, voriconazole, and posaconazole is recom-
mended for the treatment of mycotic keratitis caused
by molds [47].
However, for systemic treatment, the pharmacoki-
netic variability of the selected antifungal must be
considered [48]. Amphotericin B has poor ocular
penetration after intravenous (IV) administration and
is known to cause severe renal toxicity [33, 49].
Penetration of itraconazole into the eyes is typically
insufficient [50]. In contrast, the newer triazoles
voriconazole and posaconazole are highly bioavail-
able and demonstrate good penetration into different
parts of the eye [33].
In conclusion, our data contribute to a better
understanding of the activity of antifungals used for
treatment of disease caused by non-fumigatus Asper-
gillus species. Given the limited clinical evidence to
support the treatment of non-fumigatus Aspergillus
species, antifungal susceptibility testing may help to
guide therapy, if performed in a timely manner. The
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colorimetric microbroth growth assay may also
provide basic information on the individual effect of
static concentrations of each antifungal on these fungi.
A major limitation of the present study was the
relatively low number of strains studied. Clearly, a
wider range of isolates should be studied before any
generalizations can be made. In addition, further
dynamic in vivo modeling and clinical studies are
required to investigate the correlation between in vitro
susceptibility and in vivo clinical results.
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